Dipharma granted first CADIFA by Brazilian ANVISA for the Ursodeoxycholic Acid
Panel discussion on Custom synthesis & Contract manufacturing
CANDESARTAN CILEXETIL
Therapeutic class: Antihypertensive CAS number: 145040-37-5 Regulatory status: EU [...]
Dipharma at the XXVIII National Congress of the Italian Chemical Society
Panel discussion on Custom synthesis & Contract manufacturing
Dipharma & Flow Chemistry: Lesson at University, CNR, and Industry Meeting
Another appointment related to Dipharma’s collaboration with the academic [...]
API Production: Technology Transfer and Troubleshooting Management
The lesson by Alessio Bove, our Pilot Plant Manager [...]
ISOS 2024: Dipharma Sponsors with Key Poster Presentation
The XLVIII edition of the "Attilio Corbella" International Summer [...]
Dipharma Francis S.r.l., the Shareholders’ Meeting Appoints the New Board of Directors
Panel discussion on Custom synthesis & Contract manufacturing
Successful FDA Inspection at Dipharma Facility in Kalamazoo, MI, USA
Panel discussion on Custom synthesis & Contract manufacturing
Dipharma contributes to the U.S. Life Sciences 2024 publication
Panel discussion on Custom synthesis & Contract manufacturing
Pharma Tech Outlook awards Dipharma as one of the Top CMOs in 2024
Panel discussion on Custom synthesis & Contract manufacturing
